PCSK9 and familial hyperaldosteronism: As concerns the blood lipid profile, the directional changes observed for total cholesterol and LDL-c after treatment with PCSK9-i were in line with previous reports of Ge et al. who described similar results from PCSK9-i clinical trials involving FH subjects (Ge et al., 2021).